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ABSTRACT 
 
 
Background Foot and ankle structures are the most commonly affected in people with gout. 
However, the effect of gout on foot and ankle muscle strength is not well understood. The primary 
aim of this study was to determine whether differences exist in foot and ankle muscle strength for 
ankle plantarflexion, dorsiflexion, inversion and eversion between people with gout and age- and 
sex-matched controls. The secondary aim was to determine whether foot and ankle muscle strength 
was correlated with foot pain and disability. 
Methods Peak isokinetic concentric muscle torque was measured for ankle plantarflexion, 
dorsiflexion, eversion and inversion in 20 participants with gout and 20 matched controls at two 
testing velocities (30°/s and 120°/s) using a Biodex dynamometer. Foot pain and disability was 
measured using the Manchester Foot Pain and Disability Index (MFPDI). 
Findings Participants with gout demonstrated reduced muscle strength at both the 30°/s and 120°/s  
testing velocities for plantarflexion, inversion and eversion (p<0.05). People with gout also displayed 
a reduced plantarflexion-to-dorsiflexion strength ratio at both 30o/s and 120o/s (p<0.05). Foot pain 
and disability was higher in people with gout (p<0.0001) and MFPDI scores were inversely correlated 
with plantarflexion and inversion muscle strength at the 30°/s testing velocity, and plantarflexion, 
inversion and eversion muscle strength at the 120°/s testing velocity (all p<0.05). 
Interpretation People with gout have reduced foot and ankle muscle strength and experience 
greater foot pain and disability compared to controls. Foot and ankle strength reductions are 
strongly associated with increased foot pain and disability in people with gout.  
 
 
KEYWORDS: gout, ankle, torque, Biodex dynamometry 
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1 INTRODUCTION 
Gout is a common form of inflammatory arthritis in adults and is caused by the deposition of 
monosodium urate (MSU) crystals in articular and peri-articular structures [1]. Gout typically 
presents as episodes of acute inflammatory arthritis interspersed with intercritical asymptomatic 
periods [2]. In the presence of prolonged hyperuricaemia, chronic gouty arthritis may develop with 
degenerative joint damage, soft tissue inflammation, tophus formation and altered structural 
integrity of tendons and ligaments [2, 3]. The structures of the foot and ankle are frequently affected 
in people with gout [4, 5]. Furthermore, imaging studies have demonstrated particular patterns of 
foot involvement in gout in which the most common sites for MSU deposition are the first 
metatarsophalangeal joint, ankle joint and tendons surrounding the ankle including the peroneal 
and Achilles tendons [6-8]. 
 
People with gout report difficulty walking and experience high levels of foot pain, disability and 
impairment [9-12]. Previous studies have also shown people with gout demonstrate apropulsive gait 
patterns with reduced walking speed and cadence [10, 12]. Despite the importance of lower limb 
and foot muscle strength requirements in major daily life activities, including walking, the strength 
of foot and ankle muscles in gout is poorly understood. Quantifying muscle strength may be useful in 
establishing the biomechanical impact of gout, providing further insight into the associated 
impairments and disabilities, characterising the natural progression of the disease, and consequently 
aid in monitoring the efficacy of therapies in a clinical setting. 
 
The primary aim of this study was to determine whether there were significant differences in foot 
and ankle muscle strength for ankle plantarflexion, dorsiflexion, inversion and eversion between 
people with gout and age- and sex-matched controls. The secondary aim was to determine whether 
foot and ankle muscle strength was associated with foot pain and disability in people with gout and 
age- and sex-matched controls. It was hypothesized that those with gout would exhibit decreased 
muscle strength, and that decreased muscle strength would be associated with higher levels of foot 
pain and disability. 
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2 METHODS 
A two-arm cross-sectional study was undertaken at the Auckland University of Technology (AUT), 
New Zealand. Twenty participants with gout were conveniently sampled from patients registered 
with the Rheumatology Department at Auckland District Health Board, New Zealand. All patients 
met the 1977 preliminary American Rheumatism Association classification criteria for gout [13]. 
Twenty age- and sex-matched controls were recruited from AUT University through poster 
advertisements and staff newsletters. Ethical approval was obtained from AUT Ethics Committee 
(AUTEC 13/100). Participants were excluded if they had a history of lower limb amputation, recent 
surgery or injury to the foot or ankle, or other rheumatic condition. Gout participants were also 
excluded if they were experiencing an acute flare at the time of assessment as determined by a 
registered podiatric clinician. Demographic information including age, sex, ethnicity, body mass 
index (BMI), current medications and co-morbidities was recorded for all participants. Disease 
duration and gout clinical characteristics, including flares in preceding 3 months, and the presence 
and number of subcutaneous tophi, were recorded for the gout participants.  
 
Patient-reported foot pain and disability was assessed using the Manchester Foot Pain and Disability 
Index (MFPDI) [14]. This 19-item index measures foot-related items associated with functional 
limitation, pain, and physical appearance. Statements relating to each item were answered ‘none of 
the time’ (scored as 0), ‘on some days’ (scored as 1) and ‘on most/every day(s)’ (scored as 2) in the 
past month. A total score out of 38 was calculated for each participant. 
 
Peak isokinetic concentric muscle strength was tested by a single researcher for four conditions: 
ankle plantarflexion, dorsiflexion, inversion and eversion using the Biodex System 3 Dynamometer 
(Biodex Medical Systems, Shirley, New York). Isokinetic dynamometry has been shown to be a 
reliable tool for measuring peak torque at the ankle joint [15, 16]. For all testing conditions, 
participants were seated in the adjustable chair of the dynamometer with the hip angle set at 70° to 
85° flexion. The leg to be tested was elevated by a support arm under the knee which was flexed at 
30° to 45°. To stabilize this position, straps were fit around the participant’s torso, waist, and thigh. 
The participant’s ankle was placed on a footplate, with the heel supported in a rubber heel cup at 
90° flexion and the forefoot secured with two Velcro straps.  
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Prior to isokinetic testing each participant undertook a five minute warm up that involved walking at 
a self-selected pace. Participants were then seated in the Biodex device and the maximal range of 
motion was established for each test condition.  In addition, to negate the effect of gravity on 
torque, each limb was weighed and the data corrected by the Biodex software [17]. Prior to testing, 
each participant received a verbal explanation of each test and was asked to perform four test-
specific submaximal contractions to allow them to become familiar with each test procedure. 
Following the warm up each participant was asked to perform five maximal concentric isokinetic 
efforts. Verbal encouragement was given throughout testing. Both right and left limbs were tested 
for each condition at two velocities: 30°/s and 120°/s. Participants were given a two-minute rest 
period between each velocity condition. Participants were also given a five-minute rest period 
between plantarflexion-dorsiflexion testing and inversion-eversion testing. The maximum peak 
torque was calculated from the five contractions for each test condition and was normalised to the 
participant’s body weight prior to analysis. In addition, the strength ratios of the antagonistic muscle 
groups (plantarflexion-to-dorsiflexion and eversion-to-inversion) were also calculated. 
 
Descriptive statistics relating to participant demographics and muscle torque were presented as 
mean (SD) for continuous data and frequency (%) for categorical data. All muscle torque data was 
reviewed for normality using residuals from a linear model through both visual and formal tests 
including Kolmogorov-Smirnov and Shapiro-Wilk tests, with the participant group (gout or control) as 
the independent variable. Adjustments for gender, age group, and ethnicity were considered for 
each testing condition if they achieved at least 10% on an F test. A single adjusted model was sought 
for all testing conditions to facilitate interpretation. To determine whether the differences between 
gout and control groups were significant for each muscle test condition, mixed linear models were 
used. Models accounted for repeated measures taken from right and left feet of each participant 
through adopting a mixed models approach in which a participant-specific random effect and 
participant-nested random effect for foot-side were included. This analysis produces results identical 
to an analysis of measures averaged for each foot-side that would allow for a between-foot-side 
correlation, and also allows for any reweighting required due to missing values. For muscle groups 
which demonstrated significant between-group differences, Pearson correlation coefficients, 
denoted r, were used to assess for associations between the total MFPDI scores and muscle force. 
An r value of 0.1 was considered a small effect size, 0.3 a medium effect size, and 0.5 a large effect 
size [18]. No adjustments for multiplicity were used, but all test-statistics, their null distributions and 
their observed significance levels were reported. All data was analysed using SPSS v.20 (IBM 
Corporation) at a 5% level of significance unless otherwise noted. 
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3 RESULTS 
Participants were predominantly middle-aged European men (Table 1). The mean MFPDI score was 
significantly higher in people with gout compared to control participants.  
Descriptive statistics for peak torque were presented normalised to body weight (N·m/kg) (Table 2). 
All data conformed to a normal distribution. The participant-nested random effect for foot-side did 
not demonstrate significance for any muscle group tested. Age reached significance for all testing 
conditions (all p <0.10) and was therefore included as a covariate in the final models.  Although 
ethnicity was explored as a covariate, the numbers in each group were too small to be able to 
account for it statistically. Furthermore, boxplots of random effects by ethnicity did not conclusively 
show a marked remaining difference between ethnic categories. Age-adjusted inferential statistics 
comparing each test condition between gout and controls demonstrated differences at both the 
30°/s and 120°/s testing velocities for ankle plantarflexion (p = 0.010 and 0.008, respectively), 
inversion (p = 0.012, 0.005), and eversion (p = 0.005, 0.028), in which gout participants 
demonstrated reduced peak torque/kg values compared to controls (Table 3). No differences 
between gout and controls were observed for dorsiflexion torque/kg at either 30°/s (p = 0.280) or 
120°/s (p = 0.111) testing velocities. The plantarflexion-to-dorsiflexion torque/kg ratio was higher in 
the gout participants when compared to control participants for both 30°/s (p = 0.035) and 120°/s (p 
= 0.028) testing velocities, while no significant differences were observed between gout and control 
groups for eversion-to-inversion torque/kg ratios at either 30°/s (p = 0.285) or 120°/s (p = 0.285).  
The correlations between the MFPDI scores and muscle torque parameters showed that for people 
with gout, MFPDI scores were inversely correlated with plantarflexion at both 30°/s (r = -0.66, p < 
0.001) and 120°/s (r = -0.44, p = 0.008) testing velocities, eversion at the 120°/s testing velocity (r = -
0.36, p = 0.45) and inversion at both 30°/s (r = -0.49, p = 0.005) and 120°/s (r = -0.56, p = 0.001) 
testing velocities (Table 4). No significant correlation was observed between MFPDI scores and 
muscle torque in the control group. 
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4 DISCUSSION 
 
The aims of this study were to compare foot and ankle muscle strength in people with gout and age- 
and sex-matched controls and to determine whether strength was related to foot pain and disability. 
This study has shown that people with gout have significantly reduced plantarflexion, eversion and 
inversion muscle strength compared to controls. Consistent with our hypothesis this study has also 
demonstrated a negative correlation between these aspects of ankle strength and foot pain and 
disability in people with gout. 
 
Previous research has observed tophaceous deposition in the Achilles, peroneal and the tibialis 
posterior muscle tendons in people with gout [6, 8]. Tendons have important functional roles, both 
in generating and absorbing mechanical work during ambulation [19]. The Achilles tendon in 
particular must withstand large muscle contractions during ankle plantarflexion at propulsion, as 
well as during deceleration of body movement in the stance phase of gait [20]. Eversion and 
inversion motions of the foot, which involve the peroneal and tibialis posterior muscles, are also 
important throughout the gait cycle, particularly for their contribution to shock absorption and 
stability [21]. Although the impact that MSU deposition in these ankle structures has on muscle 
strength remains unclear, several case studies investigating tendon ruptures of the ankle and foot in 
the gout populations have suggested that the presence of tophi reduces the tensile capacity of 
tendons [22-24]. Furthermore, the infiltration of tophi into muscle tissues may potentially reduce 
the functional cross-sectional muscle area (i.e. area of active working muscle) and thereby the 
potential to generate force [25]. 
 
The reduction in plantarflexion torque and the absence of a decrease in dorsiflexion torque was also 
illustrated in the lower plantarflexion-to-dorsiflexion ratio observed in our gout participants. 
Although large strength imbalances between ankle plantarflexion and dorsiflexion are not 
considered beneficial in terms of ankle stability and function, a specific range of plantarflexion-to-
dorsiflexion ratio is important for normal walking [26]. Contrary to our hypothesis, our results 
indicate that the dorsiflexors of the ankle are not affected by strength deficits to the same extent as 
the plantarflexors of the ankle in people with gout. This finding may be related to the pattern of 
crystal deposition and patient symptoms reported in the foot and ankle, in which anterior ankle 
structures, including the tibialis anterior tendon are less frequently involved compared with the 
posterior ankle and Achilles tendon [6, 8]. Our results are consistent with previous studies 
investigating the ankle in other chronic inflammatory arthritic conditions [27] in which neural 
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(arthrogenic inhibition) and muscle volume (atrophy) changes have been found to be the main 
contributors to muscle weakness [28]. 
 
The findings from the current study are consistent with previous studies which have shown that 
foot-related pain, disability and impairment are not only features of acute gouty arthritis [9], but 
also present during intercritical periods [10, 11]. None of our gout participants were experiencing 
symptoms of acute arthritis at the time of the study which highlights the chronicity of foot pain in 
this population. Furthermore, we observed significant correlations between reduced muscle 
strength and increased MFPDI scores for plantarflexion, eversion and inversion. Although the causal 
link between muscle strength reduction and increased foot pain cannot be determined from this 
study, it is possible that foot pain may lead to muscle atrophy through disuse. Previous studies have 
observed apropulsive gait patterns consistent with pain-avoidance strategies in people with gout 
[10]. It has been proposed that such strategies would reduce plantarflexor muscle activity and the 
consequent disuse may contribute to muscle wasting [10]. 
 
This study has a number of limitations. The cross-sectional nature of the research design limits the 
ability to determine causality between patient-reported outcomes and muscle function. 
Furthermore, participants with gout were recruited from secondary care and may not be 
representative of less severe gout that is more commonly treated in primary care.  
 
Further studies may employ advanced imaging methods to explore the relationships between 
muscle strength and the presence of tophi in associated lower limb and foot musculoskeletal 
structures. Additional gout disease characteristics, including the location of recent acute gouty 
arthritis in foot and ankle structures, could also be explored in terms of their impact on local muscle 
function. The findings from this study may be useful in directing future research which evaluates 
strengthening exercises and non-pharmacological interventions which specifically target ankle 
plantarflexion, inversion and eversion musculature. Our previous research has demonstrated that 
footwear featuring rocker sole characteristics facilitates a propulsive gait in patients with gout and 
improves patient-reported outcomes [29, 30].  Further studies may also determine whether sagittal 
plane muscle weakness and altered strength ratios are also present in the knee and hip musculature.  
 
5 CONCLUSION 
In conclusion, the present study has demonstrated that muscle strength of the ankle plantarflexors 
as well as inversion and eversion of the foot is significantly reduced in people with gout. 
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Furthermore, reduced muscle strength in people with gout was strongly associated with increased 
levels of patient-reported foot pain and disability. We speculate that the muscle strength reductions 
may be a consequence of muscle atrophy secondary to pain-avoidance strategies.  
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TABLES 
 
Table 1: Demographics & clinical characteristics 
Variable Control Gout p 
N 20 20  
Gender, male, n (%) 19 (95%) 19 (95%) 0.998 
Age, years, mean (SD) 53 (12) 60 (7) 0.056 
Ethnicity, n (%) European 20 (100%) 
Maori 0 (0%) 
Pacific 0 (0%) 
Asian 0 (0%) 
European 12 (60%) 
Maori 1 (5%) 
Pacific 3 (15%) 
Asian 4 (20%) 
0.004 
BMI, kg/m2, mean (SD) 26.7 (4.3) 31.5 (5.9) 0.006 
Diuretic use, n (%) 1 (5%) 3 (15%) 0.635 
NSAID use, n (%) 0 (0%) 12 (60%) 0.998 
Prednisone use, n (%) 0 (0%) 2 (10%) 0.998 
Hypertension, n (%) 6 (30%) 12 (60%) 0.061 
Cardiovascular disease, n (%) 1 (5%) 5 (25%) 0.108 
Diabetes, n (%) 1 (5%) 4 (20%) 0.182 
Microscopically proven gout - 4 (20%) - 
Disease duration, years, mean (SD) - 16 (11) - 
Serum urate, mmol/l, mean (SD) - 0.37 (0.15) - 
Flares in preceding 3 months, mean (SD) - 1.1 (1.6) - 
Any subcutaneous tophi, n (%) - 12 (60%) - 
Subcutaneous tophus count,  mean (SD) - 3.9 (6.1) - 
Urate lowering therapy, n (%) - 18 (95%) - 
MFPDI, total score, mean (SD) 2.1 (4.3) 12.4 (8.6) 0.00001 
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Table 2: Descriptive statistics: normalised peak torque, mean (SD), N·m/kg 
Variable Foot Control Gout 
Plantarflexion 30°/s 
right 0.94 (0.39) 0.52 (0.26) 
left 1.02 (0.41) 0.53 (0.25) 
Dorsiflexion 30°/s 
right 0.42 (0.09) 0.24 (0.05) 
left 0.41 (0.11) 0.26 (0.07) 
Plantarflexion 120°/s 
right 0.67 (0.39) 0.32 (0.28) 
left 0.56 (0.25) 0.28 (0.16) 
Dorsiflexion 120°/s 
right 0.38 (0.15) 0.21 (0.04) 
left 0.35 (0.10) 0.21 (0.06) 
Eversion 30°/s 
right 0.34 (0.12) 0.23 (0.07) 
left 0.33 (0.12) 0.24 (0.08) 
Inversion 30°/s 
right 0.36 (0.15) 0.26 (0.11) 
left 0.38 (0.17) 0.23 (0.11) 
Eversion 120°/s 
right 0.22 (0.07) 0.16 (0.05) 
left 0.22 (0.08) 0.16 (0.06) 
Inversion 120°/s 
right 0.24 (0.08) 0.17 (0.07) 
left 0.25 (0.08) 0.16 (0.07) 
Plantarflexion/Dorsiflexion ratio 30°/s right 2.27 (0.79) 1.84 (1.11) 
left 2.51 (0.88) 1.63 (0.63) 
Plantarflexion/Dorsiflexion ratio  120°/s right 2.13 (0.89) 1.51 (0.96) 
left 2.05 (0.75) 1.24 (0.71) 
Eversion/Inversion ratio 30°/s right 1.01 (0.27) 1.01 (0.29) 
left 0.98 (0.32) 1.24 (0.75) 
Eversion/Inversion ratio 120°/s right 0.91 (0.15) 0.90 (0.23) 
left 1.00 (0.23) 1.08 (0.34) 
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Table 3: Inferential statistics: normalised peak torque (N·m/kg)  
Parameter Mean 
Estimate Difference 
95% CI 
p Lower Upper 
Plantarflexion 30°/s 
Control 0.94     
Gout 0.65 -0.29 -0.51 -0.07 0.010 
Dorsiflexion 30°/s 
Control 0.41     
Gout 0.37 -0.04 -0.10 0.03 0.280 
Plantarflexion 120°/s 
Control 0.51     
Gout 0.32 -0.19 -0.32 -0.05 0.008 
Dorsiflexion 120°/s 
Control 0.25     
Gout 0.22 -0.03 -0.06 0.01 0.111 
Eversion 30°/s 
Control 0.34     
Gout 0.24 -0.09 -0.16 -0.03 0.005 
Inversion 30°/s 
Control 0.37     
Gout 0.25 -0.12 -0.21 -0.03 0.012 
Eversion 120°/s 
Control 0.21     
Gout 0.17 -0.04 -0.08 -0.01 0.028 
Inversion 120°/s 
Control 0.24     
Gout 0.17 -0.07 -0.12 -0.02 0.005 
Plantarflexion/Dorsiflexion ratio 30°/s 
Control 2.33     
Gout 1.79 -0.54 -1.05 -0.04 0.035 
Plantarflexion/Dorsiflexion ratio 120°/s 
Control 2.03     
Gout 1.43 -0.60 -1.13 -0.07 0.028 
Eversion/Inversion ratio 30°/s 
Control 0.99     
Gout 1.12 0.13 -0.12 0.38 0.285 
Eversion/Inversion ratio 120°/s 
Control 0.90     
Gout 1.05 0.13 -0.12 0.38 0.285 
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Table 4: Correlations between MFPDI scores and normalised peak muscle torque (N·m/kg) 
Strength Parameter 
Control Gout 
Pearson’s r p Pearson’s r p 
Plantarflexion 30°/s 0.09 0.567 -0.66 0.00002 
Plantarflexion 120°/s 0.00 0.979 -0.44 0.008 
Eversion 30°/s 0.05 0.768 -0.28 0.117 
Eversion 120°/s 0.05 0.758 -0.36 0.045 
Inversion 30°/s -0.04 0.794 -0.49 0.005 
Inversion 120°/s -0.03 0.864 -0.56 0.001 
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Highlights 
 Peak isokinetic muscle torque of the foot and ankle was measured in people with gout 
 Plantarflexion, inversion and eversion muscle strength is reduced in people with gout 
 Reduced muscle strength is associated with increased foot pain and disability 
